Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.5K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.3K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

517
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
517
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human BMP4 mRNA Encapsulated in Lipid Nanoparticle for Bone and Articular Cartilage Repair in Aged Mice.

Journal of functional biomaterials·2026
Same author

Glycosphingolipids regulate phosphatidylserine transport machinery that operates at ER-PM contact sites.

Nature communications·2026
Same author

Investigational New Drug-enabling studies in a human vessel-chip: Are we there yet?

Bioengineering & translational medicine·2026
Same author

Telomerase is induced during wound healing across species.

Skin health and disease·2026
Same author

LATS1/2-CD38 Metabolic Rewiring Links Senescence to Intraplaque Thrombosis.

Circulation research·2026
Same author

Mitochondrial dysfunction underlies cardiac contractility and growth defects in a zebrafish model of <i>NAA15</i>-related heart disease.

bioRxiv : the preprint server for biology·2026
Same journal

A Bundle to Frame Guidelines and American Heart Association Statements.

Circulation·2026
Same journal

<i>Circulation</i> Editors and Editorial Board.

Circulation·2026
Same journal

A New <i>Circulation</i>, For You.

Circulation·2026
Same journal

Cardiovascular Risk Reduction With GLP-1 RA Drugs.

Circulation·2026
Same journal

Obesity, Severe Obesity, and Abdominal Obesity in US Youth and Adults From 1999 to 2023.

Circulation·2026
Same journal

Lipid Profile Testing and Interpretation.

Circulation·2026
See all related articles

Related Experiment Video

Updated: Mar 27, 2026

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

2.2K

Recovery From Heart Failure: Microvascular Mechanisms.

Shuang Li1, Krishan Gupta2,3, Rajul K Ranka1

  • 1Center for Cardiovascular Regeneration, Houston Methodist Research Institute, Houston, TX (S.L., R.K.R., A.J.L., F.N., M.G., K.N.C., L.L., A.M., K.A.Y., J.P.C.).

Circulation
|March 25, 2026
PubMed
Summary
This summary is machine-generated.

Left ventricular assist device (LVAD) therapy improves heart failure (HF) by reducing fibrosis and enhancing blood vessel growth. This recovery involves a cell transition regulated by c-Myc, offering new therapeutic avenues.

Keywords:
heart failureleft ventricular assist devicesingle-nucleus sequencingtransdifferentiationvascular

More Related Videos

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina
07:32

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina

Published on: June 23, 2014

14.9K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in G&#246;ttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.2K

Related Experiment Videos

Last Updated: Mar 27, 2026

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

2.2K
Assessment of Vascular Regeneration in the CNS Using the Mouse Retina
07:32

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina

Published on: June 23, 2014

14.9K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in G&#246;ttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.2K

Area of Science:

  • Cardiovascular Biology
  • Regenerative Medicine
  • Molecular Cardiology

Background:

  • Heart failure (HF) is a major global health concern.
  • Left ventricular assist devices (LVADs) bridge patients to heart transplantation and can improve cardiac function.
  • The cellular mechanisms behind LVAD-induced cardiac recovery are not fully understood.

Purpose of the Study:

  • To investigate the cellular and molecular changes in the heart following LVAD support.
  • To identify the cellular origins of vascular repair during heart failure recovery.
  • To elucidate the role of specific molecular pathways in mediating cardiac regeneration.

Main Methods:

  • Analysis of myocardial tissues from HF patients pre- and post-LVAD implantation.
  • Single-nucleus RNA sequencing to profile cellular changes.
  • Murine model of HF recovery with lineage tracing.
  • In vitro studies using patient-derived cardiac nonmyocyte cultures.
  • Assessment of cardiac function, fibrosis, and vascular density.

Main Results:

  • Post-LVAD hearts showed reduced fibrosis and increased capillary density.
  • Fibroblast abundance correlated inversely with endothelial cell abundance, suggesting angiogenesis.
  • Single-nucleus RNA sequencing revealed a fibroblast subset undergoing mesenchymal-to-endothelial transition.
  • c-Myc was identified as a key regulator of this cell fate transition.
  • Murine models recapitulated patient findings, demonstrating fibroblast-to-endothelial transition during HF recovery.

Conclusions:

  • Heart failure recovery involves reduced fibrosis and enhanced microvascularization.
  • A fibroblast-to-endothelial cell fate transition contributes to cardiac repair.
  • The transcription factor c-Myc plays a crucial role in regulating this transition.
  • These findings provide a mechanistic basis for developing regenerative therapies for heart failure.